Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: Maintaining efficacy and safety for the long haul

Archives of Dermatology

Volumn 146, Issue 2, 2010, Pages 186-188

  Gordon, Kenneth B ^a,b   Gandhi, Mona ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADD ON THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; METHODOLOGY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76749162835     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.394     Document Type: Editorial

References (21)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, I: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58 (5):826-850.
2. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA Follow-up Study. N Engl J Med. 1997;336(15):1041-1045.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, IV: guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
4. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol. 2009;145(8):937-942.
5. Lecluse LLA, Driessen RJB, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127-132.
6. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56 (1):31.e1-31.e15.
7. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842-1847.
8. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a doubleblind placebo-controlled trial. Br J Dermatol. 2005;152(5):954-960.
9. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829-835.
10. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis. J Am Acad Dermatol. 2008;58(1):106-115.
11. Gordon KB, Tyring S, Gu Y, Okun MM. Psoriasis patients treated continuously with adalimumab: efficacy and safety results from months 12 to 18. Paper presented at: the 66th Annual Meeting of the American Academy of Dermatology (AAD); February 1-5, 2008; San Antonio, TX.
12. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
13. Reich K, Nestle FO, Papp K, et al; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367- 1374.
14. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542.
15. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598-603.
16. Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis. Br J Dermatol. 2006;155(1):160-169.
17. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226-1231.
18. Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006;33(5):847-853.
19. Atzeni F, Sarzi-Puttini P, Dell'Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction. Arthritis Res Ther. 2006;8(1):R3.
20. Menter A, Korman NJ, Elmets CA, et al; American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis, III: guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
21. Taylor PC. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med. 2003;42(1):15-20.